novo nordisk semaglutide patent India Obesity Crisis: The Expiry of Ozempic's in 2026 Could Revolutionize India's Battle Against Obesity, ETPharma Novo Nordisk takes legal action

Claims described in this article as "according to the brand," "brand-stated," "per brand materials," or similar attribution language reflect what the brand has publicly stated and have not been independently substantiated by this publication

Para ofrecer la mejor experiencia, utilizamos tecnologas como las cookies para almacenar y/o acceder a la informacin del dispositivo

They can help you weigh the risks and benefits of the medication and determine whether it's right for you

Our experienced healthcare providers will work with you to determine the most appropriate infusion therapy based on your individual needs and health status

Wells Fargo declined to comment on the move.